PURPOSE: To evaluate the plain radiographic and CT findings of the necrotizing fasciitis. MATERIALS AND METHODS: We retrospectively reviewed the radiologic findings of 4 cases with necrotizing fasciitis. Three cases were proven pathologically. We evaluated pattern and extent of the gas shadows in plain films. CT findings were analysed, with emphasis on : (a) gas pattern, (b) extent, (c) location and involved site, (d) associated focal abscess, and (e) swelling of the adjacent muscles. RESULTS: On plain radiographs, four cases showed streaky or mottled gas densities in the pelvis, three cases in the perineum, one case in the abdomen, and two cases in the thigh. On CT images, gas pattern was mottled and streaky appearance with swelling of the adjacent muscles. Gasshadows located in the extraperitoneal space in four cases, fascial layer in four cases, and subcutaneous layer infour cases. There were gas shadows in pelvic wall, perineum, abdominal wall, buttock, thigh, and scrotum. Focallow density lesion suggestive of focal abscess was not visualized. CONCLUSION: Plain radiography is useful forearly diagnosis of the necrotizing fasciitis and CT is very useful for detection of precise location and extent of the disease. CT is also useful for differentiation of necrotizing fasciitis from focal abscess and cellulitis.
Abdomen ; Abdominal Wall ; Abscess ; Buttocks ; Cellulitis ; Diagnosis ; Fasciitis, Necrotizing* ; Muscles ; Pelvis ; Perineum ; Radiography ; Retrospective Studies ; Scrotum ; Thigh

Percutaneous vertebroplasty using PMMA was first performed in France by Deramond in 1984. It was later used to treat vertebral compression fractures caused by osteoporosis. With osteoporotic compression fractures, reported complication were few and minor. However, the principal risk of such a percutaneous technique is the leak of PMMA into the spinal canal or neural foramina. Despite being uncommon, major neurologic complications demand surgical interventions that prevent permanent neurologic dysfunction. We experienced a case of root compression during percutaneous vertebroplasty, which was treated by early surgical posterior decompression.
Decompression ; Fractures, Compression ; France ; Neurologic Manifestations ; Osteoporosis ; Polymethyl Methacrylate ; Spinal Canal ; Vertebroplasty*

Salmonella I 4,[5],12:i:- was a monophasic variant of Salmonella (S.) Typhimurium and notorious for re-emerging candidate which would replace S. Typhimurium DT104 for antibiotic resistance. Recently, isolation rate was increased on human and industrial animals but there was no case in domestic animals but human in Korea. This was first isolation case from domestic animals in Korea. The five isolates from feces of duck (n = 3), chicken (n = 1), and wild bird (n = 1) showed antibiotic resistance against cephems and aminoglycosides. These means that the spread of emerging bacterial pathogens to domestic animals and the need of systemic management for Salmonella I 4,[5],12:i:-.
Aminoglycosides ; Animals ; Animals, Domestic ; Birds ; Chickens ; Drug Resistance, Microbial ; Ducks ; Feces ; Humans ; Korea ; Poultry ; Salmonella

Despite the availability of direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection in Korea, need remains for pangenotypic regimens that can be used in the presence of hepatic impairment, comorbidities, or prior treatment failure. We investigated the efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for 12 weeks in HCV-infected Korean adults. Methods: This Phase 3b, multicenter, open-label study included 2 cohorts. In Cohort 1, participants with HCV genotype 1 or 2 and who were treatment-naive or treatment-experienced with interferon-based treatments, received sofosbuvir–velpatasvir 400/100 mg/day. In Cohort 2, HCV genotype 1 infected individuals who previously received an NS5A inhibitor-containing regimen ≥ 4 weeks received sofosbuvir–velpatasvir–voxilaprevir 400/100/100 mg/day. Decompensated cirrhosis was an exclusion criterion. The primary endpoint was SVR12, defined as HCV RNA < 15 IU/mL 12 weeks following treatment. Results: Of 53 participants receiving sofosbuvir–velpatasvir, 52 (98.1%) achieved SVR12. The single participant who did not achieve SVR12 experienced an asymptomatic Grade 3 ASL/ALT elevation on day 15 and discontinued treatment. The event resolved without intervention. All 33 participants (100%) treated with sofosbuvir–velpatasvir–voxilaprevir achieved SVR 12. Overall, sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir were safe and well tolerated. Three participants (5.6%) in Cohort 1 and 1 participant (3.0%) in Cohort 2 had serious adverse events, but none were considered treatment-related. No deaths or grade 4 laboratory abnormalities were reported. Conclusions: Treatment with sofosbuvir–velpatasvir or sofosbuvir–velpatasvir–voxilaprevir was safe and resulted in high SVR12 rates in Korean HCV patients.